Figure 5.

Diagnostic performance of piR-13643 and piR-21238 in the validation phase of the study. (A) The expression of piR-13643 is significantly down-regulated in tumor tissue of papillary thyroid carcinoma patients compared to normal tissue (P=0.044). (B) ROC analyses based on the expression of piR-13643 (AUC = 0.842). (C) The levels of piR-13643 increased significantly with advanced clinical stage (P = 0.0019). (D) The expression of piR-21238 is significantly upregulated in tumor tissue of papillary thyroid carcinoma patients compared to normal tissue (P =0.271). (E) ROC analyses based on the expression of piR-21238 (AUC = 0.829). (F) The levels of piR-21238 increased significantly with advanced clinical stage (P =0.0042). *P < 0.05; **P < 0.01; ***P < 0.001